Clinical features and determinants of VO2peak in de novo heart transplant recipients

doi:10.5500/wjt.v8.i5.188

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8799)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

615

HTML

4381

Figures (1-3)

239

Tables (1-3)

205

Sum=5440

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

797

Download

865

Sum=1662

Publishing Process of This Article

Item

Count

Browse

674

Download

1023

Sum=1697

Sep 10, 2018 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Clinical Trial

World J Transplantation. Sep 10, 2018; 8(5): 188-197
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.188

Clinical features and determinants of VO_2peak in de novo heart transplant recipients

Katrine Rolid, Arne K Andreassen, Marianne Yardley, Elisabeth Bjørkelund, Kristjan Karason, Julia P Wigh, Christian H Dall, Finn Gustafsson, Lars Gullestad, Kari Nytrøen

Katrine Rolid, Arne K Andreassen, Marianne Yardley, Elisabeth Bjørkelund, Lars Gullestad, Kari Nytrøen, Department of Cardiology, Oslo University Hospital, Oslo 0424, Norway

Katrine Rolid, Marianne Yardley, the Norwegian Health Association, Oslo 0307, Norway

Katrine Rolid, Marianne Yardley, Lars Gullestad, Kari Nytrøen, Faculty of Medicine, University of Oslo, Oslo 0316, Norway

Katrine Rolid, Lars Gullestad, Kari Nytrøen, KG Jebsen Center for Cardiac Research, and Center for Heart Failure Research, University of Oslo, Oslo 0316, Norway

Kristjan Karason, Department of Cardiology, Sahlgrenska University Hospital, Gothenburg 41345, Sweden

Julia P Wigh, Department of Physical Therapy, Sahlgrenska University Hospital, Gothenburg 41345, Sweden

Christian H Dall, Department of Cardiology, Bispebjerg University Hospital, Copenhagen 2400, Denmark

Finn Gustafsson, Department of Cardiology, Rigshospitalet University Hospital, Copenhagen 2100, Denmark

Author contributions: Rolid K coordinated the study, collected and analyzed the data and drafted the paper; Andreassen AK contributed to the inclusion of the participants in Norway and in further drafting of the paper; Yardley M and Bjørkelund E contributed to data collection in Norway; Karason K was responsible for the study in Sweden; Wigh JP was responsible for coordination and data collection in Sweden; Dall CH coordinated and collected data in Denmark; Gustafsson F was responsible for the study in Denmark; Gullestad L and Nytrøen K designed the research, were project leaders and participated in further drafting and analyses of the data; all authors contributed to critical revision and editing and approval of the final version.

Supported by the Norwegian Health Association, No. 12906; Scandiatransplant; and the South-Eastern Norway Regional Authority, No. 2013111.

Institutional review board statement: The study was approved by the South-East Regional Committee for medical and health research ethics in Norway and the Committee for medical and health research ethics in Sweden and Denmark.

Clinical trial registration statement: This study is registered at ClinicalTrials.gov. The registration identification number is NCT01796379.

Informed consent statement: All study participants gave their written consent prior to study inclusion.

Conflict-of-interest statement: None of the authors have any conflict of interest to declare.

CONSORT 2010 statement: We have prepared the manuscript according to the CONSORT 2010 statement, where appropriate. A pdf version of the document is uploaded.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Katrine Rolid, BSc, MSc, Physiotherapist, Department of Cardiology, Oslo University Hospital Rikshospitalet, Postbox 4950 Nydalen, Oslo 0424, Norway. katrine.rolid@medisin.uio.no

Telephone: +47-41-548328

Received: June 23, 2018
Peer-review started: June 24, 2018
First decision: July 19, 2018
Revised: July 29, 2018
Accepted: August 6, 2018
Article in press: August 6, 2018
Published online: September 10, 2018

Core Tip

Core tip: This de novo heart transplant (HTx) cohort demonstrated a median peak oxygen consumption (VO_2peak) level of 19.4 mL/kg per min at 11 ± 1.8 wk post-HTx, which is comparable to what is shown in maintenance HTx recipients. VO_2peak in this study was determined by both central and peripheral factors. The strongest predictors were O₂ pulse, heart rate reserve and muscular exercise capacity. Maximal exercise testing provides valuable information for clinical use and future prognosis and can be safely performed as early as 11 wk post-HTx.